C93.10 Chronic myelomonocytic leukemia not having achieved remission

Name of the Condition

• Chronic myelomonocytic leukemia not having achieved remission
• ICD-10 Code: C93.10

Summary

Chronic myelomonocytic leukemia not having achieved remission (CMML-NAR) is a myelodysplastic/myeloproliferative neoplasm characterized by persistent monocytosis and dysplasia in myeloid lineages, with disease activity that has not responded to treatment. This condition disrupts normal blood cell production, leading to cytopenias and potential organ infiltration. It is defined by a clinical course where remission has not been attained despite therapeutic intervention.

Causes

The development involves genetic mutations in hematopoietic stem cells, often including TET2, ASXL1, SRSF2, or RUNX1. These mutations drive uncontrolled proliferation and impaired differentiation of myeloid precursors. Secondary cases may arise from prior chemotherapy, radiation, or myelodysplastic syndromes, though de novo occurrences are more common.

Risk Factors

• Prior exposure to chemotherapy or radiation therapy
• Myelodysplastic syndromes or myeloproliferative neoplasms
• Advanced age (peak incidence in older adults)
• Male gender (slightly higher prevalence)
• Environmental exposures (e.g., benzene)

Symptoms

• Persistent fatigue or weakness
• Unexplained fever or night sweats
• Frequent infections
• Easy bruising or bleeding
• Bone or joint pain
• Abdominal discomfort due to enlarged spleen or liver
• Weight loss without effort

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and abnormalities. A bone marrow biopsy confirms the presence of leukemic cells. Additional tests, such as flow cytometry or genetic analysis, may be used to evaluate disease activity and treatment response. Documentation of persistent disease activity despite therapy is critical for coding.

Treatment Options

Treatment may include hypomethylating agents (e.g., azacitidine), targeted therapies, or supportive care to manage cytopenias. Allogeneic stem cell transplantation may be considered for eligible patients. The choice of therapy depends on disease risk, comorbidities, and prior treatment responses.

Prognosis and Follow-Up

Prognosis varies based on disease risk stratification, genetic mutations, and treatment response. Regular monitoring of blood counts, bone marrow status, and organ function is essential. Follow-up care focuses on managing symptoms, detecting progression, and adjusting therapy as needed.

Complications

• Progressive cytopenias leading to infection, bleeding, or anemia
• Organ infiltration (e.g., spleen, liver)
• Transformation to acute myeloid leukemia
• Treatment-related toxicities

Lifestyle & Prevention

• Avoid known environmental toxins (e.g., benzene)
• Maintain a balanced diet and regular exercise to support overall health
• Practice good hygiene to reduce infection risk
• Follow medical advice for managing comorbidities

When to Seek Professional Help

Seek immediate medical attention for:

• Unexplained fever or severe infections
• Excessive bleeding or bruising
• Sudden worsening of fatigue or weakness
• New or worsening abdominal pain (possible organ enlargement)

Tips for Medical Coders

Document the absence of remission status clearly in the medical record, as this is required for accurate coding of C93.10. Ensure that clinical notes specify persistent disease activity or lack of response to therapy. Verify that the diagnosis aligns with the criteria for chronic myelomonocytic leukemia and that remission has not been achieved.